Sanofi (SNY) Expected to Post Earnings on Thursday

Sanofi (NASDAQ:SNY) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Sanofi to post earnings of $1.09 per share and revenue of $12.3871 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Sanofi Price Performance

SNY opened at $44.00 on Tuesday. The company has a market capitalization of $106.67 billion, a price-to-earnings ratio of 12.29, a PEG ratio of 1.10 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The business’s fifty day simple moving average is $43.45 and its 200-day simple moving average is $45.31.

Institutional Trading of Sanofi

Institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC increased its position in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the period. Sivia Capital Partners LLC grew its position in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the period. Wealthspire Advisors LLC increased its stake in shares of Sanofi by 1,043.1% in the 4th quarter. Wealthspire Advisors LLC now owns 5,624 shares of the company’s stock valued at $273,000 after purchasing an additional 5,132 shares in the last quarter. Transamerica Financial Advisors LLC boosted its position in Sanofi by 10.4% during the second quarter. Transamerica Financial Advisors LLC now owns 5,622 shares of the company’s stock worth $272,000 after purchasing an additional 531 shares in the last quarter. Finally, Focused Alpha LLC acquired a new stake in Sanofi in the fourth quarter valued at approximately $208,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on SNY. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Hold” and a consensus target price of $49.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.